Suspension of trading
Exscientia plc Share Price
Stocks
EXAI
US30223G1022
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.840 USD | +3.20% |
|
-.--% | - |
| 21/24/21 | Exscientia plc(NasdaqGS:EXAI) dropped from S&P Global BMI Index | CI |
| 20/24/20 | Recursion Pharmaceuticals, Exscientia Complete Business Combination | MT |
| Market Cap | 50Cr 66Cr 58Cr 53Cr 94Cr 6.24TCr 94Cr 633.42Cr 245.49Cr 3.07TCr 248.2Cr 242.88Cr 11TCr | P/E 2022 |
-4.55x | P/E 2023 | -4.28x |
|---|---|---|---|---|---|
| Enterprise Value | 16Cr 21Cr 18Cr 17Cr 29Cr 1.94TCr 29Cr 197.33Cr 76Cr 956.67Cr 77Cr 76Cr 3.32TCr | EV / Sales 2022 |
1.9x | EV / Sales 2023 | 14.2x |
| Free-Float |
36.87% | Yield 2022 * |
-
| Yield 2023 | - |
| 1 day | +3.20% |
| 3 years | 3.8 |  | 9.12 |
| 5 years | 3.8 | | 30.38 |
| 10 years | 3.8 | | 30.38 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Tech/Sci/R&D Officer | 61 | 06/06/2024 | |
| Chief Tech/Sci/R&D Officer | - | 01/05/2022 | |
John Overington
CTO | Chief Tech/Sci/R&D Officer | - | 01/05/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Mario Polywka
BRD | Director/Board Member | 63 | 28/09/2017 |
Robert Ghenchev
BRD | Director/Board Member | 43 | 01/05/2020 |
Elizabeth Crain
CHM | Chairman | 61 | 12/02/2024 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.20% | -.--% | -.--% | -32.31% | 63Cr | |
| +1.44% | +1.71% | -10.63% | -9.16% | 4.27TCr | |
| +3.31% | +5.93% | +308.19% | +562.02% | 3.47TCr | |
| +2.84% | +2.14% | +6.87% | +34.93% | 3TCr | |
| -1.70% | -7.54% | +8.51% | -22.34% | 2.8TCr | |
| -1.90% | -1.56% | +11.62% | +19.80% | 2.48TCr | |
| -0.14% | +5.86% | - | - | 1.43TCr | |
| +0.68% | -1.53% | +52.04% | +107.47% | 1.31TCr | |
| -0.57% | -2.43% | +5.18% | +4.20% | 1.26TCr | |
| -0.26% | +1.15% | +100.27% | +80.69% | 1.22TCr | |
| Average | +0.69% | +0.48% | +53.56% | +82.81% | 2.13TCr | |
| Weighted average by Cap. | +0.78% | +0.90% | +65.03% | +112.78% |
| 2022 | 2023 | |
|---|---|---|
| Net sales | 2.72Cr 3.6Cr 3.14Cr 2.91Cr 5.11Cr 339.8Cr 5.14Cr 34Cr 13Cr 167.26Cr 14Cr 13Cr 580.76Cr | 2.01Cr 2.66Cr 2.32Cr 2.14Cr 3.77Cr 250.63Cr 3.79Cr 25Cr 9.86Cr 123.36Cr 9.97Cr 9.76Cr 428.35Cr |
| Net income | -12Cr -16Cr -14Cr -13Cr -22Cr -1.48TCr -22Cr -150.46Cr -58Cr -729.45Cr -59Cr -58Cr -2.53TCr | -15Cr -19Cr -17Cr -16Cr -27Cr -1.82TCr -28Cr -184.97Cr -72Cr -896.78Cr -72Cr -71Cr -3.11TCr |
| Net Debt | -49Cr -65Cr -57Cr -53Cr -92Cr -6.14TCr -93Cr -623.39Cr -241.6Cr -3.02TCr -244.27Cr -239.03Cr -10TCr | -34Cr -46Cr -40Cr -37Cr -65Cr -4.3TCr -65Cr -436.1Cr -169.01Cr -2.11TCr -170.88Cr -167.21Cr -7.34TCr |
Employees
483
- Stock Market
- Stocks
- EXAI Stock
Select your edition
All financial news and data tailored to specific country editions
